Postoperative circulating tumor DNA in stage II colon cancer: biological rationale, clinical evidence, and unresolved challenges
Erhua Yang, Xuefeng Wang, Jiajing Zhang, Dejiang Zhao, Zhimeng Yang, Xue Li, Guirong He, Tianhua Guo, Ruotian Wang, Baohong Yuan · 2026
Read Postoperative circulating tumor DNA in stage II colon cancer: biological rationale, clinical evidence, and unresolved challenges by Erhua Yang, Xuefeng Wang, Jiajing Zhang, Dejiang Zhao, Zhimeng Yang, Xue Li, Guirong He, Tianhua Guo, Ruotian Wang, Baohong Yuan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13613144.txt.
Description
Erhua Yang and nine co-authors review blood tests for leftover cancer after colon surgery. Their twenty twenty-six article deals with stage II colon cancer, where standard risk factors cannot tell who still harbors hidden disease. Circulating tumor DNA, shed by tumors into blood, can flag that minimal residual disease.
The review sums the biology, the test methods, and the trial evidence. A positive test after surgery tracks a much higher risk of relapse than clinic factors alone. One large study found about a twelvefold risk gap. A guided-care trial showed testing can cut chemotherapy use without harming relapse-free survival. The authors stress an asymmetry: a negative result may justify less treatment, but a positive one does not yet pick the right extra treatment.
Catalog record
| CREATOR | Erhua Yang, Xuefeng Wang, Jiajing Zhang, Dejiang Zhao, Zhimeng Yang, Xue Li, Guirong He, Tianhua Guo, Ruotian Wang, Baohong Yuan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |